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Abstract: Anaplastic large cell lymphoma (ALCL) is a mature T-cell lymphoma that can present as
a systemic or primary cutaneous disease. Systemic ALCL represents 2% to 5% of adult lymphoma
but up to 30% of all pediatric cases. Two subtypes of systemic ALCL are currently recognized on the
basis of the presence of a translocation involving the anaplastic lymphoma kinase ALK gene. Despite
considerable progress, several questions remain open regarding the pathogenesis of both ALCL subtypes.
To investigate the molecular pathogenesis and to assess the relationship between the ALK(+) and ALK(-
) ALCL subtypes, we performed a genome-wide DNA profiling using high-density, single nucleotide
polymorphism arrays on a series of 64 cases and 7 cell lines. The commonest lesions were losses at
17p13 and at 6q21, encompassing the TP53 and PRDM1 genes, respectively. The latter gene, coding
for BLIMP1, was inactivated by multiple mechanisms, more frequently, but not exclusively, in ALK(-
)ALCL. In vitro and in vivo experiments showed that that PRDM1 is a tumor suppressor gene in ALCL
models, likely acting as an antiapoptotic agent. Losses of TP53 and/or PRDM1 were present in 52% of
ALK(-)ALCL, and in 29% of all ALCL cases with a clinical implication.
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Key Points
• The commonest lesions
in anaplastic large cell
lymphomas are losses
at 17p13 and at 6q21,
concomitant in up to one-
quarter of the cases.
• PRDM1 (BLIMP1) gene
(6q21) is inactivated by
multiple mechanisms and
acts as a tumor suppressor
gene in anaplastic large B-cell
lymphoma.
Anaplastic large cell lymphoma (ALCL) is a mature T-cell lymphoma that can present as a
systemic or primary cutaneous disease. Systemic ALCL represents 2% to 5% of adult lym-
phoma but up to 30% of all pediatric cases. Two subtypes of systemic ALCL are currently
recognized on the basis of the presence of a translocation involving the anaplastic lym-
phoma kinase ALK gene. Despite considerable progress, several questions remain open
regarding the pathogenesis of both ALCL subtypes. To investigate the molecular patho-
genesis and to assess the relationship between the ALK1 and ALK2 ALCL subtypes, we
performed a genome-wide DNA profiling using high-density, single nucleotide poly-
morphism arrays on a series of 64 cases and 7 cell lines. The commonest lesions were
losses at 17p13 and at 6q21, encompassing the TP53 and PRDM1 genes, respectively.
The latter gene, coding for BLIMP1, was inactivated by multiple mechanisms, more
frequently, but not exclusively, in ALK2ALCL. In vitro and in vivo experiments showed
that that PRDM1 is a tumor suppressor gene in ALCL models, likely acting as an
antiapoptotic agent. Losses of TP53 and/or PRDM1 were present in 52% of ALK2ALCL,
and in 29% of all ALCL cases with a clinical implication. (Blood. 2013;122(15):2683-2693)
Introduction
Anaplastic large cell lymphoma (ALCL) is a mature T-cell lym-
phoma with either a systemic or primary cutaneous disease (cALCL)
presentation.1,2 Systemic ALCL represents a small subset of adult
lymphomas (2%-5%), but up to 30% of pediatric cases. Systemic
ALCLs are currently stratiﬁed on the presence or absence of a
translocation involving the anaplastic lymphoma kinase ALK gene.1
ALK1ALCL most frequently occur among children or young adults,
while ALK2ALCL cases are more often observed among elderly
people.3 Although several studies have shown that ALK1ALCL has
a signiﬁcantly better outcome than ALK2ALCL, when ALCL
patients are stratiﬁed according to the clinical parameters (mostly
age and/or stage), both subsets display similar failure-free and
overall survival (OS) rates.3
The ALK1ALCL subset most frequently carries the t(2;5)
(p23;q35) fusing ALK to the nucleophosmin (NPM) gene.4,5 All
ALK fusions have a constitutive activation of the catalytic domain
of the ALK tyrosine kinase, leading to the phosphorylation and
activation of several downstream pathways favoring in lymphoma
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survival, growth, and/or regulating the proliferation and cell-cycle
control.4 Besides 2 translocations, more frequent among cALCL than
systemic ALK2ALCL,6-9 the molecular events responsible for the
pathogenesis of ALK2ALCL cases are still largely unknown. Because
ALCL is a relatively rare disease, only few studies regarding the
genomic analysis of ALCL are available,5,10-13 often composed by few
samples and analyzed with low-resolution techniques. Nevertheless,
genomic lesions have been observed in the 2 ALCL subsets: ALK1
ALCL can carry chromosomal imbalances including loss of 4q13-q28,
6q13-q22, 11q14-q23, and 13q and gains of 7p11-pter and chromosome
17.6,8-11 Conversely, ALK2ALCL generally presents a more complex
genomic proﬁling respect to ALK1ALCL, and shows gains of 1q41-
qter, 5q, 6p, 7p, 8q, 12q, and 17q and losses of 6q21-q22 and 13q.6,8-11
To disclose the molecular pathogenesis and to assess the relation-
ship between ALK1 and ALK2 ALCL subtypes, we performed
genome-wide DNA proﬁling using high-density, single nucle-
otide polymorphism (SNP) arrays on a relative large series of
primary ALCL samples and ALK1ALCL cell lines.
Material and methods
Tumor panel
Clinical specimenswere derived from involved sites and obtained in the course
of routine diagnostic procedures, before therapy. Diagnoses were made
following the recommended criteria.1 Caseswere selected on the availability of
frozen material with a fraction of neoplastic cells in the specimen representing
.70% of overall cellularity as determined by morphologic and/or immuno-
phenotypic studies. Informed consent was obtained in accordance to the
Helsinki Declaration following the procedures approved by the local ethical
committees and institutional review boards of each participating institution.
The study was approved by the Bellinzona ethical committee.
Genome-wide DNA profiling
Genome-wide DNA proﬁles were obtained using the Genome-Wide Human
SNP Array 6.0 (Affymetrix), and analyzed as described.14,15
Mutational analysis
Whole-genome ampliﬁcation (WGA) was performed as described,16 and all
PRDM1 coding exons and TP53 exons 4 to 8 were polymerase chain reaction
(PCR) ampliﬁed (primers in supplemental Table 1, available on theBloodWeb
site), and sequenced as described.16Mutations were conﬁrmed by independent
PCR from non-WGA DNA, and germline polymorphisms (obtained from the
NCBI SNP database or present in available matched normal DNA) were
discarded. The presence of a copy-neutral loss of heterozygosity (LOH) at the
PRDM1 gene locus was assessed using dChipSNP (www.dchip.org).17
Methylation analysis
The methylation status of the PRDM1 gene promoter was investigated by
bisulﬁte sequencing PCR method. DNA samples (500 ng) underwent
bisulphite modiﬁcation using the EZDNAMethylation kit (ZymoResearch).
PCR was performed with primers speciﬁc for converted bisulﬁte converted
DNA (supplemental Table 1) designed with MethPrimer,18 and the amplicons
Figure 1. Genomic aberrations in ALCL samples. (A) Frequency of DNA gains (up) and losses (down) observed in 64 systemic ALCL (top panel), 31 ALK2ALCL (middle panel),
and 33 ALK1ALCL samples (bottom panel). Red represents gains and blue represents losses. X-axis represents chromosome localization and physicalmapping; y-axis, proportion of
cases showing theaberrations. (B-C)Representation of focal aberrations inALCLsamples. Analysis viaGISTIC of copy number gains (left) and losses (right) for the 64ALCLsamples
and only for the 31 ALK2ALCL samples. False-discovery rate q values are plotted along the x-axis with chromosomal position along the y-axis. Altered regions with significant levels
exceeding the vertical green line (significance threshold) were deemed significant. Chromosomal positions are shown for each significant region on the right side of the plots.
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were visualized on agarose gels. PCR products were puriﬁed using the QIAquick
PCR Puriﬁcation kit (Qiagen), and paired-end sequenced (Mycrosynth).
Immunohistochemistry
Formalin-ﬁxed, parafﬁn-embedded sections of 38 ALCL cases from the
University of Turin Department of Pathology were stained on a semiautomated
immunostainer (Bond-Max; Leica Microsystems). Brieﬂy, parafﬁn-embedded
sections were ﬁrst dewaxed, and epitope retrieval was performed in 0.01M
citrate buffer, pH 6.0. Antibodies used were anti–PRDM-1 (1:20, mouse
monoclonal ROS195G,19 kindly provided by Dr Giovanna Roncador, Centro
Nacional de Investigaciones Oncolo´gicas, Madrid, Spain). Slides were analyzed
by light microscopy and reviewed by 2 independent operators.
Figure 1 (Continued).
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FISH
Fluorescence in situ hybridization (FISH) has been performed as previously
described,20 using PRDM1 gene probe (RP1-134E15,21 kindly provided by
Dr Laura Pasqualucci, Institute for Cancer Genetics, New York, NY) and,
as control, Cep6 probe (RP11-164C22).
Cell lines
Established human cell lines SUDHL1, SupM2, SupM2-TS, JB6, L82,
Karpas 299 (ALK1ALCL), FE-PD (ALK2ALCL), MAC-1 (cALCL) were
cultured with RPMI media supplemented with fetal bovine serum (10%) and
penicillin-streptomycin-neomycin (Sigma-Aldrich).
Lentiviral infection
Packaging cells were transfected with PRDM1 cloned in pWPI lentiviral
vector (kindly provided by Dr Laura Pasqualucci) in combination with third-
generation helper plasmids. The viral supernatant was collected after 48
hours, ﬁltered, and SupM2-TS, SUDHL1, and JB6 ALCL cells were infected.
One cycle of infection was performed. Cells were collected at different days
after infection; RNA and proteins were extracted and then processed,
respectively, for real-time PCR and western blotting analysis.
Evaluation of infection efficiency
Cells infected with pWPI-HA-BLIMP1 or the control cells (cells infected
with empty vector and cells not transfected) were harvested and washed once
in phosphate-buffered saline (PBS) and analyzed using a FACScan ﬂow
cytometer (Becton Dickinson). The analysis of the percentage of green
ﬂuorescent protein (GFP)–positive cells was performed using CellQuest
Pro software (Becton Dickinson).
Cell proliferation
Cells infected with pWPI-HA-BLIMP1 and the control cells (cells infected
with empty vector and cells not transfected) were recovered and an equal
number of cells were plated in triplicates. Cells were collected and counted
daily up to 10 days after the recovery.
Evaluation of cell death and cell-cycle analysis
Cells infected with pWPI-HA-BLIMP1 and the control cells were harvested
and washed once in PBS and then stained with propidium iodide (PI) (1mg/mL;
Sigma-Aldrich) in PBS and analyzed using a FACScan ﬂow cytometer.
The analysis of the percentage of cell death was performed using CellQuest
Pro software.
Cells infected with pWPI-HA-BLIMP1 and the control cells were har-
vested at different time points, washed once in PBS. and then ﬁxed in 70%
ethanol at 4°C for at least 1 hour. Cells were stained with PI (50 mg/mL;
Sigma-Aldrich) in PBS containing RNAse-A (75 kU/mL; Sigma-Aldrich)
and analyzed for DNA content using the FACScan ﬂow cytometer. The
analysis of cell cycle was performed using the FlowJo software (TreeStar).
Western blotting analysis
Cells were solubilized in hot sodium dodecyl sulfate (SDS) lysis buffer and
sonicated for 15 seconds. The protein content was determined using the BCA
protein assay (Pierce Chemical Co). Lysates were fractionated by 8%
SDS–polyacrylamide gel electrophoresis (SDS-PAGE). Membranes were
incubated with anti-PRDM1 (6D3, SC-47732; Santa Cruz Biotechnology)
anti-a–glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (MAB374;
Millipore), anti-Actin (MAB1501R; Millipore) or anti-GFP (2555; Cell
Signaling Technology) overnight, followed by the appropriate horseradish
peroxidase–conjugated anti-mouse or anti-rabbit secondary antibodies
(Amersham Life Science) for 1 hour. Enhanced chemiluminescence
detection was then done following the manufacturer’s instructions (Amersham
Life Science). Equal loading of samples was conﬁrmed by probing for GAPDH
or Actin.
Real-time PCR
Total RNA was extracted using TRIzol reagent (Invitrogen) and puriﬁed
using the RNeasy total RNA Isolation kit (Qiagen). The concentration of
total RNA was determined spectrophotometrically at 260 nm using
NanoDrop (NanoDrop Technologies). One microgram of total RNA was
reverse-transcribed using the Superscript First-Strand Synthesis System for
the RT-PCR kit (Invitrogen) according to the manufacturer’s instructions.
Real-time PCR ampliﬁcation was performed using Fast SYBRGreenMaster
Mix on a StepOnePlus Real-Time PCR System (Applied Biosystems), with
primers (supplemental Table 1) designed using Primer3.22 All samples were
analyzed in triplicates. The messenger RNA (mRNA) relative quantities for
each sample were calculated based onmean cycle threshold (Ct) values using
the D-D Ct correcting for experimental variations by GAPDH normalization.
Gene expression profiling
Gene expression proﬁling (GEP) was performed on 3 biologic replicates for
each condition of Supm2-TS cells using the HumanHT-12v4 Expression
BeadChip (Illumina), as described.23 Data were ﬁrst extracted with the
Illumina GenomeStudio software and then imported in GenomicsSuite 6.4
(Partek) and quantile normalized. Differentially expressed transcripts were
identiﬁed by analysis of variance (ANOVA) (fold change, .1.5; false dis-
covery rate, ,0.2).
Mice and in vivo experiments
Male NSG (NOD/Shi-scid/IL-2Rgnull) mice, chosen for the rate of engraft-
ments they manifest,24 were injected subcutaneously with 1 3 106 SupM2-
TS cells infected with empty vector or with vector for PRDM1 reexpression
in both ﬂanks. Tumor growth was measured over time. At day 20, tumors
were explanted and analyzed. Mice were treated properly and ethically in
accordance with European Community guidelines.
Analysis of clinical data
OS was calculated from the time of diagnosis to the last follow-up or death
of any cause. The log-rank test was used to investigate the impact on OS of
categorical variables. The cumulative probability of OS was plotted as a
curve according to the Kaplan-Meier method. Statistical analyses were
performed with Stata/SE version 12.1 (StataCorp).
Results
Genomic profiling of ALCL
Genome-wide DNA proﬁling was performed on clinical specimens
of 64 ALCL cases (31 ALK2ALCL and 33 ALK1ALCL) and
7 ALCL cell lines (5 derived from ALK1, 1 ALK2ALCL, and
1 cALCL) (Figure 1A; supplemental Figure 1). Supplemental Table 2
reports the main clinical and pathological characteristics of patients.
ALK1 and the ALK2ALCL clearly differed in terms of genomic
proﬁles (Figure 1A). The minimal common regions (MCRs), which
should encompass the loci likely containing the pathogenetic genes,
were calculated for the whole series of 64 clinical ALCL specimens
(Table 1). The most common losses affected 17p13.3-p12 (25%), in
which TP53 gene is located, and 6q21 (17%), the region that en-
compassed PRDM1 and ATG5. Other common losses were iden-
tiﬁed at 13q32.3-q33.3 and 16q23.2 (16%). More than 20% of
ALCL samples presented gains of different regions of the long arm
of chromosome 1, while 8q24.22 was gained in 16% of cases.
ALK2ALCL displayed recurrent lesions at a higher frequency
than ALK1ALCL. Losses of 17p13.3-p12 and 6q21 were observed in
42% and 35%, respectively, and losses of distal regions of chromosome
13, 12q, and 10 were identiﬁed in.20% of the cases. Gains at 1q were
observed in almost 30% of ALK2ALCL. ALK1ALCL presented less
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lesions or at a lower frequency than ALK2ALCL: only gains of 1q,
7q32.3, and 7p22.3-p21.3 were observed in .15% of samples.
To further deﬁne regions containing genes with putative tumor-
igenic potential, we applied the Genomic Identiﬁcation of Signiﬁ-
cant Targets in Cancer (GISTIC) 2.0 algorithm,25 which identiﬁes
aberrations occurring at a frequency higher than expected by chance,
giving particular relevance to loci targeted by DNA ampliﬁcations
or homozygous deletions.25 GISTIC identiﬁed a limited series of
regions of gains and of losses (Figure 1B-C; supplemental Tables 3-4).
The most signiﬁcant aberrations were the losses at 17p13.1 (TP53)
and at 6q21 (PRDM1 and ATG5), both among all ALCL samples
and within the ALK2ALCL cases. GISTIC highlighted the loss at
14q11.2, region in which the T-cell receptor a (TCRa) locus is
located. Because this deletion is likely due to the physiological
rearrangements taking place in T cells, we discarded it from further
analyses. The most signiﬁcant gain in ALCL was at the 9p24.1
region (JAK2, CD274, PDCD1LG2, UHRF, KMD4C), while gains
at 20q11.2 (ASIP, AHYC, ITCH,MIR644), at 11p13 (APIP, PDHX,
CD44) and at 13q31.3 (MIR17HG) were identiﬁed in both ALK1
and ALK2 ALCL, being more signiﬁcant in the latter entity.
PRDM1 gene is often inactivated in ALCL
Both MCR analysis and GISTIC pointed to 6q21 loss as one of the
most signiﬁcantly recurrent lesion. The minimally affected region
encompassed 1120 kb including 2 genes: PRDM1 and ATG5
(Figure 2A). We observed losses at 6q21 in 11 of 31 (35%) ALK2
samples, in 4 of 5 (80%) ALK1 cell lines, and in 1 of 33 (3%)
Table 1. Most frequent recurrently affected regions detected in 64 ALCL samples
Lesion/Cytoband Start* Size, kb* RefSeq genes† ALCL % ALK2ALCL % ALK1ALCL % P
Losses
17p13.3-p12 526 11 747.22 .20 (TP53) 25 42 9 .002
6q21 105 944 900 951.75 ATG5, PRDM1 19 56 6 ,.001
13q32.3-q33.3 99 090 837 9349.42 .20 16 23 9 ns
16q23.2 78 371 498 11 642 MAF, WWOX 16 29 3 .004
Gains
1q 121 344 093 127 880.29 .20 23 32 15 ns
8q24.22 133 799 280 919.4 NDRG1, PHF20L1, SLA, ST3GAL1, TG, WISP1 17 23 12 ns
P values were calculated between ALK1ALCL and ALK2ALCL frequencies.
ns, not significant.
*Numbering according to Genome Reference Consortium Human Build 37 (GRCh37) (hg19).
†According to the NCBI RefSeq database.
Figure 2. PRDM1 gene is inactivated in ALCL samples. (A) Representation of the aberrations, and their size, affecting the PRDM1 locus (6q21). Blue bars represent loss; light
blue bars represent homozygous deletion (hdel). (B) Results of sequencing and mutational analysis of PRDM1 coding exons in 46 ALCL samples (31 ALK2 and 15 ALK1 samples)
and in 7 ALCL cell lines (5ALK1and 1 ALK2 cell line and 1 cALCL). Red triangles are newmutations in 2 different ALK2 samples. (C) View of the single nucleotide changes in different
sequences. (D) Immunohistochemistry results for BLIMP1 staining: BLIMP1 staining was evaluated on TMA obtained from an independent series of ALCL samples. TMA samples
were considered negative or positive for BLIMP1 depending on the intensity of the staining. A representative case for each condition, BLIMP1 negative (left panel), BLIMP1 positive
only at cytoplasmic level (middle panel), BLIMP1 positive only at a nuclear level (right panel), is reported (magnification, 340). TMA, tissue microarray.
BLOOD, 10 OCTOBER 2013 x VOLUME 122, NUMBER 15 GENOMIC PROFILING OF ALCL 2687
ALK1 cases. A PRDM1 homozygous loss was detected in a single
ALK1 case. Deletion at level of 6q21 locus has been validated with
FISH analysis on all ALCL cell lines and in 3 of the clinical
specimens bearing PRDM1 loss (supplemental Figure 2).
To evaluate whether this gene could also be inactivated by somatic
mutations, we sequenced all coding exons of the PRDM1 gene. To
evaluate whether the gene could also be inactivated by somatic
mutations, we sequenced PRDM1 gene coding exons in all ALK2
Figure 3. PRDM1 is a tumor suppressor gene in an in vitro model of ALCL. (A) PRDM1/BLIMP1 mRNA and protein level after infection with empty vector (pWPI) or
vector for BLIMP1 reexpression (pWPI-HA-BLIMP1). (B) Percentage of GFP-positive cells after infection at 72 hours and 96 hours. (C) Percentage of growing cells after
infection at 72 hours. *P 5 .017. (D) Growth curve after infection, cells counted at days 3, 5, and 7 after infection. (E) Percentage of dead cells after infection at 72 hours and
96 hours. (F) Cell-cycle profile after infection.
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ALCL, all cell lines, and in 15 of 33 ALK1ALCL. Two mutations
were detected in ALK2 tumors, generating a stop codon (Figure 2B-C).
One of these cases showed a copy-neutral LOH, while the other
displayed the loss of the wild-type allele, suggesting a complete
inactivation of the protein. We also analyzed the methylation
proﬁle of the PRDM1 gene promoter region in 40 of 69 ALCL
samples, but no clear methylation was detected.
PRDM1 was inactivated, by deletion or by somatic mutations, in
12 of 31 (39%) and in 1 of 33 (3%) of the clinical specimens derived
from ALK2 and ALK1 ALCL, respectively, and in 4 of 5 (80%)
ALK1 cell lines.
We then evaluated (by immunohistochemistry) the expression of
PRDM1 protein on a series of 38 clinical specimens of ALCL, inclu-
ding 4 samples analyzed by DNA proﬁling. The protein was ex-
pressed at nuclear level in at least 10% of the neoplastic cells in 13 of
21 (62%) of ALK1 and 8 of 15 (53%) of ALK2ALCL. Two ALK2
ALCL samples presented an exclusively cytoplasmic staining of
PRDM1 (Figure 2D): 1 had a 6q21 loss and a PRDM1 stop codon
mutation, possibly determining the aberrant protein localization.
PRDM1 is a tumor suppressor gene in an in vitro model of ALCL
To understand the role of PRDM1 loss in ALCL, we studied the
consequences of the reexpression of the gene, using lentiviral vec-
tors, in the SupM2-TS cell line, an ALK1ALCL cell line with the
same 6q21 loss observed in clinical specimens. Cells transduced
with the pWPI-HA-BLIMP1 vector reexpressed PRDM1 at both the
mRNA and the protein level (Figure 3A). The percentage of GFP-
positive cells infected with empty vector increased over time with
a concomitant decrease in the fraction of GFP-positive cells after
PRDM1 reexpression (Figure 3B), suggesting that the enforced
PRDM1 expression in an ALK1ALCL cell line, bearing PRDM1
loss, exerted a negative selective pressure.
We then evaluated whether the reexpression of PRDM1 gene
could have an effect in terms of proliferation and apoptosis. Dif-
ferently from control SupM2-TS cells (transduced with the empty
vector), PRDM1 reconstituted cells underwent growth arrest, which
was more marked starting from the third day after infection
(Figure 3C-D). Concomitant to the proliferation arrest, we also
observed amoderate increase in the percentage of apoptotic cells after
PRDM1 transfection (23% vs 29% at 72 hours and 12% vs 17% at
96 hours) with an increase of the sub-G1 phase (8% vs 15%;P, .001).
We observed also cell-cycle arrest comparing cells after infection with
empty vector or with vector for PRDM1 reconstitution (G1: 49% vs
25%, P, .0001; S: 19% vs 13%, P, .001; and G2-M: 21% vs 31%,
P , .05) (Figure 3E-F). Results were conﬁrmed on 2 additional
ALK1ALCL cell lines, SUDHL1 and JB6 (supplemental Figure 3).
PRDM1 exerts a prosurvival effect
To understand the transcriptional role of PRDM1 in ALCL, we
carried out GEP in the SupM2-TS cells, infected with lentivirus
pWPI or pWPI-HA-BLIMP1. Supervised analysis identiﬁed a limited
number of genes modulated by PRDM1 reexpression (Figure 4),
.70% of them upregulated after PRDM1 reconstitution. Among the
differentially expressed transcripts, there were IRF4 and MIR155HG
(downregulated), important for normal T-cell physiology and known
to be deregulated in ALCL.8,9,26-31 The top upregulated genes also
included transcripts involved in growth and cell proliferation inhibition
(SERPINA3, KHDRBS3), apoptosis (S100A9, PMAIP1), and cell-
cycle arrest (RASSF2). Because MIR155HG is a direct repressor of
the proapoptotic factor SHIP1,32-35 we analyzed SHIP1 levels after
Figure 4. Hierarchical clustering of samples analyzed with GEP. GEP analysis
was performed in untreated Supm2-TS cells (n 5 3), Supm2-TS cells 72 hours after
infection with empty vector (pWPI; n 5 3) and Supm2-TS cells after infection with
lentivirus for BLIMP1 reconstitution (pWPI-HA-BLIMP1; n 5 3).
BLOOD, 10 OCTOBER 2013 x VOLUME 122, NUMBER 15 GENOMIC PROFILING OF ALCL 2689
BLIMP1 reexpression: SHIP1 mRNA levels were upregulated after
BLIMP1 reconstitution.
PRDM1 is a tumor suppressor gene in an in vivo model of ALCL
To further validate the in vitro data, we prepared pWPI-HA-BLIMP1
lentivirus for PRDM1 reexpression and pWPI empty vector for con-
trol for in vivo experiments using the SupM2 cell line, obtaining
;50% of GFP-positive cells as read out of the efﬁciency of trans-
fection. We then injected the cells in mice as follows: 3 mice infected
with lentivirus for PRDM1 and 3 mice infected with empty vector.
Tumors were explanted at day 20 after inoculum and reanalyzed by
ﬂow cytometry. Figure 5A shows that the percentage of GFP-positive
cells in mice injected with PRDM1-positive cells was dramatically
reducedwith respect to the percentage of GFP-positive cells of control
mice, suggesting that PRDM1-positive cells had growth impairment
in vivo. These results were conﬁrmed at protein level (Figure 5B).
Xenograft growth curves of control and PRDM1-transduced SupM2
cells in NSG mice indicated that the latter cells grew less than
controls, supporting the in vitro experiments (Figure 5C).
PRDM1 inactivation is associated with 17p losses and affects
the clinical outcome
Figure 6A shows a heatmap of all the 64 ALCL cases, ranked as
the most common recurrent lesions. Losses at 6q21, encompassing
the PRDM1 gene locus, and losses at 17p often co-occurred with
(P , .001). We investigated whether TP53, the tumor suppressor
gene mapped at 17p13, was also inactivated by somatic mutations in
cases without genomic loss. We analyzed the mutational status of
coding exons from 4 to 8, the most common affected by mutations
in other lymphomas,36 in 11 ALK2 cases, 6 with PRDM1 loss and no
17p loss and 6 with both genes apparently nonaffected. In accordance
with published articles,37,38 no TP53 gene mutations were identiﬁed
in any of the clinical specimens, while we conﬁrmed the presence of
the TP53mutations in cell lines39,40 (Karpas-299, in exon8; SU-DHL-
1, in exon 8; L82, in exon 7).
Based on the heatmap, 4 groups of ALCL could be identiﬁed:
ALK2ALCL with PRDM1 inactivation and/or 17p loss (16 of 31
ALK2ALCL, 52%); ALK2ALCL bearing nor PRDM1 inactivation
nor 17p loss (15 of 31 ALK2ALCL, 48%); ALK1ALCL with ge-
nomic aberrations (15 of 33 ALK1ALCL, 45%); and ALK1ALCL
without additional aberrations (18 of 33 ALK1ALCL, 55%). Of
clinical relevance, the group of patients with ALK2ALCL and bearing
PRDM1 and/or 17p loss presented an inferior OS (Figure 6B), which
was particularly evident when this group of cases was compared
against all the remaining systemic ALCL cases (P 5 .007) (supple-
mental Figure 4). Because of the limited size of the our cohort we could
not speculate whether the inferior OS observed in the ALK2ALCL
group could be attributable mostly or entirely to TP53 deletion rather
than PRDM1 loss. However, a recent case presenting wild-type TP53
Figure 5. PRDM1 is a tumor suppressor gene in vivo. (A) Percentage of GFP-positive cells in tumors explanted from mice infected with empty vector (pWPI) or with vector
for BLIMP1 reexpression (pWPI-HA-BLIMP1). (B) Protein levels of BLIMP1 and GFP in tumors explanted from mice at day 20. A vertical line has been inserted to indicate
a repositioned gel lane. (C) Xenograft growth curves of infected cells in NSG mice.
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and c-MYC genes, but PRDM1 gene loss, showed a very aggressive
and fatal clinical course (Giorgio Inghirami, personal oral commu-
nication, July 2013). Also, due to the sample size, we could not
investigate in detail the observed differences of ALK1ALCL with
or without lesions different from 17p loss or 6q21 loss.
Discussion
Our results, obtained on a large series of ALCL samples studied by
SNP array, showed that (1) the commonest lesions are losses at
17p13 and at 6q21, encompassing the TP53 and PRDM1 genes; (2)
PRDM1 (BLIMP1) gene is inactivated by multiple mechanisms,
more frequently, but not exclusively, in ALK2ALCL; (3) PRDM1 is
a tumor suppressor gene in ALCL, as shown by both in vitro and in
vivo experiments, likely acting as an antiapoptotic agent; and (4) the
inactivation of both TP53 and PRDM1 genes is often concomitant
and present in almost one-quarter of cases, possibly affecting the
clinical outcome.
As expected,5,10-13 ALK1ALCL presented less genomic aberra-
tions than ALK2ALCL, highlighting the extensive transforming acti-
vity owned by ALK fusion proteins.4 However, ALK1 and ALK2
subsets also shared different genomic aberrations, indicating that the
2 subsets might undergo similar transforming events.41 Our results
could conﬁrm the presence of some but not all of the lesions previ-
ously reported in ALCL5,10-13: discrepancies could be due to the
different techniques that have been used, to the usual limited sizes
of the series, and to the adopted diagnostic criteria, especially to
deﬁne ALK2ALCL.
We observed a 6q21 loss in both ALK1 and ALK2 specimens,
with much higher frequency in the latter subtype. PRDM1, mapped
in the 6q21 minimal common region, was inactivated by DNA
losses, copy-neutral LOH and somatic mutations, as in diffuse
large B-cell lymphoma (DLBCL)42,43 and natural killer (NK) T-cell
lymphoma.44,45 The inactivation was usually monoallelic, suggest-
ing a haploinsufﬁciency effect, similar to that mainly seen in NK T-
cell lymphoma,44,45 in which, however, it might be associated with
promoter methylation,45 not detected in our series.
In vitro functional studies and in vivo experiments provided evi-
dence that PRDM1 is a bona ﬁde tumor suppressor gene in ALCL.
The reintroduction of a functional PRDM1 in an ALCL cell line
presenting the same loss observed in patients demonstrated the
capacity of this gene to lead to cell proliferation impairment, cell-
cycle block, and apoptosis. The high rate of PRDM1 deletion ob-
served in ALK1 cell lines, severalfold higher than ALK1ALCL
cases and even exceeding the frequency in ALK2ALCL clinical
specimens, further suggests that PRDM1 inactivation might im-
prove the chances of survival of the neoplastic cells. GEP following
PRDM1 reexpression indicated that PRDM1 inactivation might exert
its function regulating 2 main factors, MIR155HG and IRF4, which
are central to a complex regulatory loop. We have observed that the
loss of BLIMP1 might sustain the constitutive high expression of
MIR155HG (miR-155) and IRF4 while negatively regulate PMAIP1
(NOXA) and INPP5D (SHIP1) expression. MIR155HG is often
overexpressed in lymphomas,28 including ALCL, amongwhichALK2
cases have higher levels than ALK1 cases.29,31 IRF4 is deregulated
in cALCL,8,9 and its expression is necessary for the survival of the
activated B-cell DLBCL and multiple myeloma cells.46,47 More-
over, INPP5D, a negative regulator of cell proliferation, could be
suppressed by both MIR155HG and IRF4,32-35 and IRF4 positively
regulates MIR155HG32 while suppressing PMAIP1,48 which can
increase MIR155HG levels.
Figure 6. Distribution of main genomic aberration in ALK1 and ALK-ALCL and their impact on outcome. Heatmap with the relative distribution of the most common
lesions detected in ALCL samples (A) and Kaplan-Meier graph showing OS in systemic ALCL according to ALK status and to the presence of PRDM1 inactivation and/or TP53
loss (B). In panel A: red, presence; gray, absence. In panel B: x-axis, months; y-axis, percentage of alive patients.
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The role of PRDM1 in normal and neoplastic T cells is not clear
contrary to its established role in normal and/or neoplastic B cells.
The fundamental role of PRDM1 toward the plasma cell differ-
entiation is reﬂected in the expression pattern observed in the 2 main
subtypes of DLBCL, germinal center B-cell–like (GCB) DLBCL
and activated B-cell–like (ABC) DLBCL, and in its inactivation
limited to the DLBCL subgroup.42,43 Here, we have observed
inactivation of the PRDM1 gene in approximately one-quarter of
ALCLs, particularly in ALK2ALCL, while the protein was expressed
in half of the ALCL cases, irrespective of the ALK status, similar to
what was reported in another previous series of cases.19 Although we
could speculate that the frequently observed PRDM1 loss (in a
heterozygous way) in the ALK2ALCL subset did not affect protein
expression detected in the immunohistochemistry assay, due to the
low overlap between the series analyzed by genomic proﬁling or by
immunohistochemistry, and also due to the still limited knowledge
on ALCL in general, further studies will be necessary to clarify the
relationship between protein expression and genetic lesions. Of
interest, 1 ALK2ALCL case presented 6q21 loss on 1 allele, a stop
codon mutation on the second allele, and it expressed aberrant
cytoplasmic PRDM1 protein expression.
In our series, 6q21 losses were signiﬁcantly associated with 17p
deletions. The TP53 gene (17p13) or other transcripts mapped on
chromosome 17 might act as tumor suppressor gene(s) and co-
operate with PRDM1 loss in the ALCL pathogenesis. ALCL cases
with deletion affecting 6q21 and/or 17p had a poorer outcome. Due
to the relatively limited series of evaluable cases and due to the
heterogeneous type of given treatments, this observation requires
validation on an independent series of homogenously treated patients.
Finally, genomic proﬁling identiﬁed lesions, such as ampliﬁca-
tions of 9p24.1 (JAK2) and 13q31.3 (MIR17HG), which suggest
possible therapeutic targets. Both transcripts are involved in the
regulation of the MYC gene,49 which was also recurrently gained,
and MIR17HG is associated with phosphatidylinositol 3-kinase/
AKT/mammalian target of rapamycin pathway activation.50 Thus,
our data provide the rationale for the evaluation of new targeted
therapies such as Janus kinase 2 inhibitors, MYC/Bromodomain
inhibitors, and AKT/mTOR inhibitors in ALCL patients.
In conclusion, our data provide evidence from genomic studies,
functional analysis, and in vivo experiments that PRDM1 is a bona ﬁde
tumor suppressor gene in ALCL. Genomic proﬁling identiﬁed ALCL
subgroups with potential clinical and therapeutic signiﬁcance.
Acknowledgments
This work was supported by Oncosuisse grant KLS-02403-02-2009,
Anna Lisa Stiftung, Nelia et Amadeo Barletta Foundation, AIRC
5x1000 (Genetics-Driven Targeted Management of Lymphoid
Malignancies Italy), F.E.S. R.2007-13 (Immonc), Converging Tech-
nologies (Modeling Oncogenic Pathways: From Bioinformatics to
Diagnosis and Therapy, BIO_THER), Fonds Tom Debackere,
Stefanie’s Rozen Fonds.
M.B. is enrolled in the Program in Pharmaceutical Sciences,
University of Geneva (Geneva, Switzerland).
Authorship
Contribution: M.B. interpreted data, performed validation and func-
tional experiments, and cowrote the manuscript; A. Rinaldi performed
genomic proﬁling; I.K. performed statistical analysis and interpreted
data; P.B. helped in performing functional experiments; M.T. and
F.T. performed in vivo experiments; R.P. and E.Z. provided advice;
P.M.V.R. performed statistical analysis; A.M., B.T., T.T., S.M.R.-P.,
M.A.P., S.B., E.C., G.B., S.H.S., A. Rosenwald, M.P., K.H.Y., P.P.P.,
R.D., and S.P. collected and characterized tumor samples; G.I. designed
research, collected and characterized tumor samples, provided advice,
and cowrote the manuscript; F.B. designed research, performed
statistical analysis, interpreted data, and cowrote the manuscript;
and all authors have approved the ﬁnal manuscript.
Conﬂict-of-interest disclosure: The authors declare no compet-
ing ﬁnancial interests.
The current afﬁliation for G.I. is the Department of Pathology
and Laboratory Medicine, Weill Cornell Medical College/New York
Presbyterian Hospital, New York, NY.
Correspondence: Francesco Bertoni, Lymphoma and Genomics
Research Program, IOR Institute of Oncology Research, Lymphoma
Unit, IOSI Oncology Institute of Southern Switzerland, via Vincenzo
Vela 6, CH-6500Bellinzona, Switzerland; e-mail: frbertoni@mac.com;
and Giorgio Inghirami, Department of Pathology and Laboratory
Medicine, Weill Cornell Medical College/New York Presbyte-
rian Hospital, 525 East 68th St, New York, NY 10065; e-mail:
inghig01@gmail.com.
References
1. Swerdlow SH, Campo E, Harris NL,
et al, eds. WHO Classification of Tumours of
Haematopoietic and Lymphoid Tissues. Lyon,
France: IARC Press; 2008.
2. Fornari A, Piva R, Chiarle R, Novero D, Inghirami
G. Anaplastic large cell lymphoma: one or more
entities among T-cell lymphoma? Hematol Oncol.
2009;27(4):161-170.
3. Savage KJ, Harris NL, Vose JM, et al;
International Peripheral T-Cell Lymphoma Project.
ALK- anaplastic large-cell lymphoma is clinically
and immunophenotypically different from both
ALK1 ALCL and peripheral T-cell lymphoma, not
otherwise specified: report from the International
Peripheral T-Cell Lymphoma Project. Blood.
2008;111(12):5496-5504.
4. Barreca A, Lasorsa E, Riera L, et al; European
T-Cell Lymphoma Study Group. Anaplastic
lymphoma kinase in human cancer. J Mol
Endocrinol. 2011;47(1):R11-R23.
5. Boi M, Stathis A, Zucca E, Inghirami G, Bertoni F.
Genetic alterations in systemic nodal and
extranodal non-cutaneous lymphomas derived
from mature T cells and natural killer cells. Cancer
Sci. 2012;103(8):1397-1404.
6. Feldman AL, Law M, Remstein ED, et al.
Recurrent translocations involving the IRF4
oncogene locus in peripheral T-cell lymphomas.
Leukemia. 2009;23(3):574-580.
7. Feldman AL, Dogan A, Smith DI, et al.
Discovery of recurrent t(6;7)(p25.3;q32.3)
translocations in ALK-negative anaplastic
large cell lymphomas by massively parallel
genomic sequencing. Blood. 2011;117(3):
915-919.
8. Pham-Ledard A, Prochazkova-Carlotti M,
Laharanne E, et al. IRF4 gene rearrangements
define a subgroup of CD30-positive cutaneous
T-cell lymphoma: a study of 54 cases. J Invest
Dermatol. 2010;130(3):816-825.
9. Wada DA, Law ME, Hsi ED, et al. Specificity
of IRF4 translocations for primary cutaneous
anaplastic large cell lymphoma: a multicenter
study of 204 skin biopsies. Mod Pathol. 2011;
24(4):596-605.
10. Ott G, Katzenberger T, Siebert R, et al.
Chromosomal abnormalities in nodal and
extranodal CD301 anaplastic large cell
lymphomas: infrequent detection of the t(2;5) in
extranodal lymphomas. Genes Chromosomes
Cancer. 1998;22(2):114-121.
11. Zettl A, Ru¨diger T, Konrad MA, et al. Genomic
profiling of peripheral T-cell lymphoma,
unspecified, and anaplastic large T-cell lymphoma
delineates novel recurrent chromosomal
alterations. Am J Pathol. 2004;164(5):1837-1848.
12. Salaverria I, Bea` S, Lopez-Guillermo A, et al.
Genomic profiling reveals different genetic
aberrations in systemic ALK-positive and
ALK-negative anaplastic large cell lymphomas.
Br J Haematol. 2008;140(5):516-526.
13. Youssif C, Goldenbogen J, Hamoudi R, et al.
Genomic profiling of pediatric ALK-positive
anaplastic large cell lymphoma: a Children’s
2692 BOI et al BLOOD, 10 OCTOBER 2013 x VOLUME 122, NUMBER 15
Cancer and Leukaemia Group Study. Genes
Chromosomes Cancer. 2009;48(11):1018-1026.
14. Rinaldi A, Kwee I, Young KH, et al. Genome-wide
high resolution DNA profiling of hairy cell
leukaemia. Br J Haematol. 2013;162(4):566-569.
15. Chigrinova E, Rinaldi A, Kwee I, et al. Two
main genetic pathways lead to the transformation
of chronic lymphocytic leukemia to Richter
syndrome [published online ahead of print
September 4, 2013]. Blood.
16. Mensah AA, Rinaldi A, Ponzoni M, et al. Absence
of NOTCH1 gene mutations in MALT lymphomas.
Br J Haematol. 2012;157(3):382-384.
17. Lin M, Wei LJ, Sellers WR, Lieberfarb M, Wong
WH, Li C. dChipSNP: significance curve and
clustering of SNP-array-based loss-of-
heterozygosity data. Bioinformatics. 2004;20(8):
1233-1240.
18. Li LC, Dahiya R. MethPrimer: designing primers
for methylation PCRs. Bioinformatics. 2002;
18(11):1427-1431.
19. Garcia JF, Roncador G, Garcı´a JF, et al. PRDM1/
BLIMP-1 expression in multiple B and T-cell
lymphoma. Haematologica. 2006;91(4):467-474.
20. Inghirami G, Macri L, Rosati S, Zhu BY, Yee HT,
Knowles DM. The Reed-Sternberg cells of
Hodgkin disease are clonal. Proc Natl Acad Sci U
S A. 1994;91(21):9842-9846.
21. Pasqualucci L, Compagno M, Houldsworth J,
et al. Inactivation of the PRDM1/BLIMP1 gene in
diffuse large B cell lymphoma. J Exp Med. 2006;
203(2):311-317.
22. Untergasser A, Nijveen H, Rao X, Bisseling T,
Geurts R, Leunissen JA. Primer3Plus, an
enhanced web interface to Primer3. Nucleic Acids
Res. 2007;35(Web Server issue):W71-W74.
23. Bonetti P, Testoni M, Scandurra M, et al.
Deregulation of ETS1 and FLI1 contributes to the
pathogenesis of diffuse large B-cell lymphoma
[published online ahead of print August 7, 2013].
Blood.
24. Tabbo F, Barreca A, Machiorlatti R, et al.
Humanized NOD/Scid/IL2g2/2 tumor grafts
recapitulate primary anaplastic large cell
lymphoma. Annual meeting of the American
Association for Cancer Research; April 6-10,
2013; Washington, DC. Abstract 3853.
25. Mermel CH, Schumacher SE, Hill B, Meyerson
ML, Beroukhim R, Getz G. GISTIC2.0 facilitates
sensitive and confident localization of the targets
of focal somatic copy-number alteration in human
cancers. Genome Biol. 2011;12(4):R41.
26. Han Y, Amin HM, Franko B, Frantz C, Shi X,
Lai R. Loss of SHP1 enhances JAK3/STAT3
signaling and decreases proteosome degradation
of JAK3 and NPM-ALK in ALK1 anaplastic large-
cell lymphoma. Blood. 2006;108(8):2796-2803.
27. Honorat JF, Ragab A, Lamant L, Delsol G,
Ragab-Thomas J. SHP1 tyrosine phosphatase
negatively regulates NPM-ALK tyrosine kinase
signaling. Blood. 2006;107(10):4130-4138.
28. Lawrie CH. MicroRNAs and lymphomagenesis:
a functional review. Br J Haematol. 2013;160(5):
571-581.
29. Merkel O, Hamacher F, Laimer D, et al.
Identification of differential and functionally active
miRNAs in both anaplastic lymphoma kinase
(ALK)1 and ALK- anaplastic large-cell lymphoma.
Proc Natl Acad Sci U S A. 2010;107(37):
16228-16233.
30. Cretney E, Xin A, Shi W, et al. The transcription
factors Blimp-1 and IRF4 jointly control the
differentiation and function of effector regulatory
T cells. Nat Immunol. 2011;12(4):304-311.
31. Liu C, Iqbal J, Teruya-Feldstein J, et al. MicroRNA
expression profiling identifies molecular
signatures associated with anaplastic large cell
lymphoma [published online ahead of print June
25, 2013]. Blood.
32. Wang L, Toomey NL, Diaz LA, et al. Oncogenic
IRFs provide a survival advantage for Epstein-
Barr virus- or human T-cell leukemia virus type
1-transformed cells through induction of BIC
expression. J Virol. 2011;85(16):8328-8337.
33. Trotta R, Chen L, Costinean S, et al.
Overexpression of miR-155 causes expansion,
arrest in terminal differentiation and functional
activation of mouse natural killer cells. Blood.
2013;121(16):3126-3134.
34. Pedersen IM, Otero D, Kao E, et al. Onco-miR-
155 targets SHIP1 to promote TNFalpha-
dependent growth of B cell lymphomas. EMBO
Mol Med. 2009;1(5):288-295.
35. O’Connell RM, Chaudhuri AA, Rao DS, Baltimore
D. Inositol phosphatase SHIP1 is a primary target
of miR-155. Proc Natl Acad Sci U S A. 2009;
106(17):7113-7118.
36. Xu-Monette ZY, Medeiros LJ, Li Y, et al.
Dysfunction of the TP53 tumor suppressor gene
in lymphoid malignancies. Blood. 2012;119(16):
3668-3683.
37. Cesarman E, Inghirami G, Chadburn A, Knowles
DM. High levels of p53 protein expression do not
correlate with p53 gene mutations in anaplastic
large cell lymphoma. Am J Pathol. 1993;143(3):
845-856.
38. Rassidakis GZ, Thomaides A, Wang S, et al. p53
gene mutations are uncommon but p53 is
commonly expressed in anaplastic large-cell
lymphoma. Leukemia. 2005;19(9):1663-1669.
39. Hu¨binger G, Mu¨ller E, Scheffrahn I, et al. CD30-
mediated cell cycle arrest associated with induced
expression of p21(CIP1/WAF1) in the anaplastic
large cell lymphoma cell line Karpas 299.
Oncogene. 2001;20(5):590-598.
40. Drakos E, Atsaves V, Schlette E, et al. The
therapeutic potential of p53 reactivation by nutlin-
3a in ALK1 anaplastic large cell lymphoma with
wild-type or mutated p53. Leukemia. 2009;23(12):
2290-2299.
41. Piva R, Agnelli L, Pellegrino E, et al. Gene
expression profiling uncovers molecular
classifiers for the recognition of anaplastic large-
cell lymphoma within peripheral T-cell neoplasms.
J Clin Oncol. 2010;28(9):1583-1590.
42. Mandelbaum J, Bhagat G, Tang H, et al. BLIMP1
is a tumor suppressor gene frequently disrupted in
activated B cell-like diffuse large B cell lymphoma.
Cancer Cell. 2010;18(6):568-579.
43. Nishikawa K, Nakashima T, Hayashi M,
et al. Blimp1-mediated repression of negative
regulators is required for osteoclast differentiation.
Proc Natl Acad Sci U S A. 2010;107(7):
3117-3122.
44. Karube K, Nakagawa M, Tsuzuki S, et al.
Identification of FOXO3 and PRDM1 as
tumor-suppressor gene candidates in NK-cell
neoplasms by genomic and functional analyses.
Blood. 2011;118(12):3195-3204.
45. Ku¨c¸u¨k C, Iqbal J, Hu X, et al. PRDM1 is
a tumor suppressor gene in natural killer cell
malignancies. Proc Natl Acad Sci U S A. 2011;
108(50):20119-20124.
46. Shaffer AL, Emre NC, Lamy L, et al. IRF4
addiction in multiple myeloma. Nature. 2008;
454(7201):226-231.
47. Yang Y, Shaffer AL III, Emre NC, et al. Exploiting
synthetic lethality for the therapy of ABC diffuse
large B cell lymphoma. Cancer Cell. 2012;21(6):
723-737.
48. Piya S, Moon AR, Song PI, et al. Suppression of
IRF4 by IRF1, 3, and 7 in Noxa expression is
a necessary event for IFN-g-mediated tumor
elimination. Mol Cancer Res. 2011;9(10):
1356-1365.
49. Klapproth K, Wirth T. Advances in the
understanding of MYC-induced
lymphomagenesis. Br J Haematol. 2010;149(4):
484-497.
50. Rao E, Jiang C, Ji M, et al. The miRNA-17;92
cluster mediates chemoresistance and enhances
tumor growth in mantle cell lymphoma via PI3K/
AKT pathway activation. Leukemia. 2012;26(5):
1064-1072.
BLOOD, 10 OCTOBER 2013 x VOLUME 122, NUMBER 15 GENOMIC PROFILING OF ALCL 2693
